It is well accepted that downregulation of BRCA1 and BRCA2 leads to PARP inhibitor sensitivity, and our data suggest that TIGAR KD induces “BRCAness” by phenocopying the gene expression pattern produced by BRCA1/2 downregulation and thereby sensitizes cancer cells to olaparib. The gene discussed is PARP1; the disease is cancer.